May 06, 2008

HistoMag: Nanomaterials in Medical Physics

immunoperoxidase stain in breast histologyLong ago when I used to be a medical student, my Anatomy teacher said that the breasts were an ornament to a lady and it gave motherhood to a woman. The words still reverberate in my ears. This aesthetic organ is frequently targeted by cancer. Put in other way, cancer of the breast is the second most common cancer worldwide (lung cancer tops the list) among both the sexes, and the most common type of cancer in women.

Diagnosing cancerous cells have been a nightmare for pathologists. We can not define a normal cell properly and differentiating them with cancerous cells can be pretty tough. Apart from their detection by radiological investigations which include X-rays, CT scan, MRI and other imaging modalities; we depend heavily on tissue biopsy samples collected from the patient's suspected specimen. We then stain the specimen using various dyes and examine them under the microscope.

For example, in the above picture, a section of breast tissue has been stained with immunoperoxidase. Such staining employs targeting and latching onto a tissue antigen of interest by using an external antibody (the immuno part), and then making these tissue antigens visible by the formation of a colored product by catalytic reactions brought about by peroxidase.

Now scientists have gone one step further. In some cancers of the breast there is an overexpression of a protein (antigen) called HER2/neu (Erb B2). This is a transmembrane protein, meaning that this molecule has an extracellular domain, a membrane spanning portion and an intracellular part. The peculiar nomenclature derives from the fact that this molecule is in fact a receptor for human epidermal growth factor and was found in rat neuroblastoma cell lines. Surprisingly, HER does not seem to have a physiological ligand, making the receptor look like a lady who does not have a mate! tyrosine kinase activation and downstream effectsThe protein when over-expressed, may form complexes among themselves, thereby transactivating its inherent tyrosine kinase activity. Unleashing the tyrosine kinase activity results in a cascade of activity that fosters tumorigenesis (picture on the left).

Scientists are now tagging magnetic nanoparticles with antibody to HER2/neu. Trastuzumab (herceptin), as the antibody is known, is a humanized monoclonal antibody (only one type/clone of molecule). Thus magnetic nanoparticles attaches to HER proteins (via trastuzumab); the density (intensity) of which can then be probed by applying the specimen to a magnetic field and extrapolating the the distortion these nanoparticles induce in them. Researchers at University College London (UCL) in the UK have developed HistoMag system which uses this technology. HistoMag with its coils, for cancer detection using SQUIDA drive coil (picture shown) produces a magnetic field which is made to vary with time, and a magnetometer using SQUID (superconducting quantum-interference device) as the pick up coil. The tissue section was sandwiched in the middle. Apart from detection of malignant cells it is also capable of predicting what population of women are likely to benefit from Herceptin (Trastuzumab) therapy. (In passing, it may be said that the same magnetometer device is being developed further so that it may, one day be able to pick-up your thoughts non invasively.) Many different approaches are cropping up which use nanotechnology, optical imaging and other modalities for the imaging of tissue sections. Quentin Pankhurst, professor of physics at UCL, the man behind HistoMag, has previously developed and commercialized SentiMag, a device which detects sentinel lymph nodes (lymph nodes first to enlarged in cancer).

In another development, researchers at the University of Debrecen, Debrecen, Hungary and Max Planck Institute for Biophysical Chemistry, Göttingen, Germany, have used paramagnetic microspheres coated with ligands (Herceptin) to attach to HER2. They then used confocal laser microscopy and digital image processing to 'see' the trans-activation (of ErbB2 (HER-2)). In confocal laser microscopy, a laser light is thrown into the sample through a special dichroic mirror, which allows light of one (long) wavelength to pass and that of other (short) wavelengths to reflect. When a laser of blue color (say) strikes the sample, which has been treated with a fluorescent dye, light of another wavelength say green is emitted. The dichromatic mirror now filters the blue light, while letting the green light pass, which is then amplified by photomultiplier tube and visualized. They found this to be an efficient tool in assessing Erb (HER2) activation, signal propagation and heterodimer formation.

In vivo neoplasms may be imaged by administering the patient a dose of these nanomagnets by mouth or by injection, and then imaging the patient. A modification of the device will be necessary.
ResearchBlogging.org
Friedländer, E., Arndt-Jovin, D.J., Nagy, P., Jovin, T.M., Szöllősi, J., Vereb, G. (2005). Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: Local stimulation using magnetic microspheres as assessed by quantitative digital microscopy. Cytometry Part A, 67A(2), 161-171. DOI: 10.1002/cyto.a.20173
Last modified: never
Reference: hyper-links, unless otherwise mentioned

2 comments:

Anonymous said...

Can you please comment on the possibility/effectiveness of MRI use in the early breast cancer detection?

AmiyaMax said...

Newer generations of MRI is better in detecting "early breast cancer" than their former counterparts. However, due to its high "sensitivity", false positive cases may be reported, leading to more/unwanted treatment.

Please read more at the American Cancer Society:http://www.cancer.org/docroot/NWS/content/NWS_1_1x_MRI_May_Alter_Treatment_For_Early_Stage_Breast_Cancer.asp